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Abstract: The World Health Organization (WHO) estimates that 2.3 billion people will be 
overweight and 700 million obese in 2015. The reasons for this disastrous trend are 
attributed to the global tendency toward the reduced magnitude of exercise and physical 
activity and the increased dietary intake of fats, sugars and calories with reduced amount of 
vitamins and minerals. To prevent life-style-related diseases, like Metabolic Syndrome 
(MS), researchers’ attention is increasingly focusing on some of the so called “functional 
foods” which may be useful for their prevention and treatment. One of these functional 
ingredients is fucoxanthin (FX), a characteristic carotenoid present in edible brown 
seaweeds, such as Undaria pinnatifida (Wakame), Hijikia fusiformis (Hijiki), Laminaria 
japonica (Ma-Kombu) and Sargassum fulvellum. The increasing popularity of this 
molecule is certainly due to its anti-obesity effect, primarily detected by murine studies. 
These works revealed FX mediated induction of  uncoupling protein-1 (UCP-1) in 
abdominal white adipose tissue (WAT) mitochondria, leading to the oxidation of fatty 
acids and heat production in WAT. Beyond this important role, in recent studies FX has 
shown a great antioxidant activity, anti-cancer, anti-diabetic and anti-photoaging properties. 
The aim of this review is to highlight the main effects of FX on human health.  
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1. Introduction  
Cardiovascular diseases (CVD), cancer, and other chronic diseases are nowadays the most frequent 
causes of death. They all share a multifactorial origin and are caused by a complex interaction between 
genetic predisposition and personal life style [1]. For this reason an exclusively pharmacological 
treatment is not always sufficient and, among other factors, nutrition plays a vital contributory or 
protective role [2]. According to the 2005 survey by the World Health Organization (WHO), globally 
1.6 billion people (over 15 years of age) are overweight (body mass index or BMI ≥ 25), and   
400 million are obese (BMI ≥ 30). Recently, there has been a rapid increase in the incidence of obesity 
not only in developed countries such as Europe and USA, but also in developing countries, and it is 
estimated that in 2015 the number of overweight people will be 2.3 billion and thereof 700 million 
obese people. WHO reported that the reasons for this disastrous trend are attributed to the global 
tendency toward the reduced magnitude of exercise and physical activity and the increased dietary 
intake of fats, sugars and calories with reduced amount of vitamins and minerals. To prevent life-style-
related diseases, like the metabolic syndrome (MS), it is important to rectify the poorly balanced 
nutritional conditions of habitual diet. Researchers are focusing on many functional ingredients in 
foods which may be useful for the prevention and treatment of life-style-related diseases [3], among 
them fucoxanthin (FX).  
2. Definition and Characterization 
FX is a characteristic orange colored carotenoid present in edible brown seaweeds, such as Undaria 
pinnatifida (Wakame), Hijikia fusiformis (Hijiki), Laminaria japonica (Ma-Kombu) and Sargassum 
fulvellum. It belongs to the class of non-provitamin A carotenoids, a class of 40-carbon organic 
molecules that consists of two groups: xanthophylls (when their structure contains oxygen) and 
carotenes (without oxygen in chemical formula). FX is a xanthophyll whose distinct structure includes 
an unusual allenic bond, epoxide group, and conjugated carbonyl group in polyene chain with 
antioxidant properties [4,5].  
Marine algae can be divided into two groups, namely microalgae and macroalgae (seaweeds).   
There are about 6000 species of seaweed divided into three main classes: green (chlorophytes),   
red (rhodophytes) and brown (phaeophytes). Brown seaweeds are the major class, contributing 
approximately to the 59% of the total culture production in 2006, followed by red (40%) and green 
(<1%) seaweeds. Especially brown seaweeds contain many types of bioactive compounds such as 
omega-3 polyunsaturated fatty acids (PUFAs), polyphenols, polysaccharides, fucosterol, and FX. 
Algal polyphenols possess many biological activities, including anti-inflammatory, hepatoprotective, 
anti-tumor, anti-hypertensive and HIV-1 reverse transcriptase activities as well as anti-diabetic activity 
based on the inhibition of α-glucosidase [6]. Anticarcinogenic effects, apoptosis induction on cancer 
cells, anti-inflammatory effects, and radical scavenging activity are known biological activities of   
FX [7–9]. The antioxidant properties of carotenoids have been suggested as being the main mechanism 
by which they afford their beneficial health effects [10]. However, it would be difficult to explain all 
the physiological effects of carotenoids solely by their antioxidant activity. In the last few years 
nutrigenomics studies have focused on the exceptional ability of FX in modulating the expression of Mar. Drugs 2012, 10              
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specific genes involved in cell metabolism [11]. This last feature seems to be the main healthy effect  
of FX. 
3. Metabolism 
3.1. Animal Studies 
Recently, absorption and metabolism of FX in mice was investigated. Dietary administered FX was 
converted to amarouciaxanthin A via fucoxanthinol in mice [12,13]. This metabolic conversion was 
also observed in human hepatoma cell (HepG2) and required NAD(P)
+ as cofactor [14]. Dietary FX is 
hydrolyzed to fucoxanthinol in the gastrointestinal tract by digestive enzymes such as lipase and 
cholesterol esterase and then converted to amarouciaxanthin A in the liver [15,16]. Thus, these 
metabolites are considered to be the active forms that exert physiological functions in the body. 
Amarouciaxanthin A is stored in abdominal white adipose tissue (WAT), fucoxanthinol in other 
tissues. The bioavailability of these metabolites is required for the proper and safe usage of dietary FX. 
Recent studies have described the pharmacokinetics of FX and its metabolites, and demonstrated their 
accumulation after oral administration to mice [17]. Dietary FX undergoes de-acetylation in small 
intestine becoming fucoxanthinol, which enters the systemic bloodstream through lymphatic duct. 
Some fucoxanthinol is reduced to amarouciaxanthin A in the liver; the remaining part is accumulated 
in the tissues [18]. 
3.2. Human Studies 
Currently there are few data about pharmacokinetics of FX and its metabolites in human subjects. 
Recent studies reported that fucoxanthinol was detectable in human plasma after the daily intake of 
wakame. Data about pharmacokinetics of FX demonstrated that bioavailability and metabolism of 
fucoxanthinol is higher in humans than in mice [18,19]. Mordenti et al. [20] reported that smaller, 
short-lived animals generally clear drugs from their bodies more rapidly than larger, long-lived 
animals, and that the pharmacokinetic profile of different species was strikingly different, elimination 
being most rapid for mice and least rapid for human subjects among the species compared. 
FX absorption rate is generally affected by the composition of food matrix. The solubility of FX in 
soybean oil and in other vegetable oils is very low, while FX can easily dissolve in medium-chain 
triacylglycerols (MCT) or in fish oil [21]. Antioxidants such as vitamin E are generally used in the 
products of unstable carotenoids such as astaxanthin and FX to protect against oxidation. However, 
solubility of FX into vitamin E is very low. It is possible to easily mix FX with vitamin E using MCT 
as a medium [22]. Thus, the higher anti-obesity effect of FX with MCT in comparison with FX alone, 
would be due to the increase in FX absorption rate and oxidative stability. When the UCP1 expression 
in WAT was compared between mice fed with purified FX and seaweed lipids containing FX, the 
higher UCP1 level was found in the mice fed seaweed lipids, although the FX content was the same in 
both groups [22]. This suggests that the absorption rate of FX is strongly affected by the presence of 
other components, especially lipids.  Mar. Drugs 2012, 10              
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4. Toxicity 
Japanese researchers performed single and repeated oral dose toxicity studies of FX in order to 
evaluate the safety of this carotenoid. In the single dose study, FX was orally administered to male and 
female mice at doses of 1.000 and 2.000 mg/kg. In the repeated doses study, FX at doses of 500 and 
1.000 mg/kg was orally administered for 30 days. In both studies, no mortality and no abnormalities in 
gross appearance were observed. In the repeated doses study, histological observation revealed no 
abnormal changes in liver, kidney, spleen and gonadal tissues of any of the FX-treated groups [23]. 
Another group of researchers tested FX-containing oil extracted from microalga, Chaetoseros sp. in 
rats. Single oral dose and 13-week oral subchronic toxicity studies were conducted. In the single oral 
dose study, no mortality and no change related to the test material were observed. Thus, the 50% lethal 
dose of microalgal FX oil is more than 2.000 mg/kg body weight. In the 13-week oral dose study, 0.20 
or 200 mg/kg body weight of microalgal FX oil was administered. The FX-administered groups, 
showed no mortality and no abnormalities. This result suggested that the no observed adverse effect 
level of FX-containing oil extracted from microalga Chaetoseros sp. was 200 mg/kg body weight 
under the tested subchronic dose condition [24]. 
5. Health Properties 
5.1. Antioxidant Activity 
Oxidation is a normal metabolic process, an inevitable consequence of the energy production in 
mitochondria. This process removes one of the two electrons from oxygen molecules, forcing them to 
steal an electron from other molecules, causing oxidative damage [25]. Oxidative stress establishes 
when there is an imbalance between production of free radicals (FRs) and the body’s ability to 
neutralize them. Carotenoids have been implicated as important dietary nutrients with antioxidant 
potential. Firstly, they can quench singlet oxygen. This reaction is attributed mainly to a physical 
mechanism whereby the excess energy of singlet oxygen is transferred to the long central chain of 
conjugated double bonds in the carotenoid molecule. The carotenoid with added energy is excited to 
the triplet state and, upon losing the energy as heat, relaxes to the singlet state without any change in 
structure [26].  
Another role of carotenoids as antioxidants is attributed to their scavenging of FRs, which steal an 
electron from the carotenoid or form an adduct with it. Electron-rich carotenoids are more suitable for 
reaction with FRs. Consequently, the ability of carotenoids to quench singlet oxygen increases with 
increasing number of conjugated double bands [27]. FX acts as an antioxidant under anoxic conditions 
whereas other carotenoids have practically no quenching abilities. Most animal tissues under 
physiological conditions have low oxygen presence. Furthermore, the typical antioxidants are usually 
proton donors (ascorbic acid, α-tocopherol, glutathione). FX, on the other hand, donates electron as a 
part of its free-radical quenching function. A combination of these distinct properties is very rarely 
found among naturally occurring food-derived compounds [28]. High levels of oxidative stress are 
common in many diseases including atherosclerosis, Parkinson’s disease, Alzheimer’s disease, acute 
myocardial infarction, chronic fatigue syndrome and fibromyalgia. These diseases are very different, Mar. Drugs 2012, 10              
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but share the same biochemical imbalance. Thus, FX could become a new weapon to prevent and treat 
these diseases. 
5.2. Anti-Cancer Activity 
FRs and oxidative stress are clearly involved in the pathogenesis of cancer disease, so carotenoids, 
by means of their antioxidant properties, are considered effective anti-cancer molecules. Many studies 
showed the anti cancer properties of FX especially against prostate cancer, human leukemia, and 
human colon cancer cell lines [29]. The main mechanism is suggested to be the regulatory effect of FX 
on biomolecules related to apoptosis and cell cycle. The molecular mechanisms proposed are the FX 
mediated inhibition of cell cycle by inducing cell cycle arrest and enhancing gap junctional intercellular 
communication. Recent studies reported the involvement of the caspase pathway and the regulation of 
Bcl expression (Bcl-2 and Bcl-xL) in apoptosis induction by FX [30–32]. 
Recently researchers found that FX induces cell cycle arrest in G2/M phase and apoptosis in human 
gastric cancer MGC-803 cells with the inhibition of growth in MGC-803 cell by FX resulting from cell 
cycle arrest and apoptosis. Down-regulation of surviving, CyclinB1 by FX might contribute to the 
anti-cancer effects of FX, which may reduce CyclinB1 expression through JAK/STAT signal pathway, 
sequentially inhibiting proliferation of MGC-803 cells [33]. 
Moreover FX and fucoxanthinol induced cell growth arrest and apoptotic cell death in primary 
effusion lymphoma (PEL), a rare type of non-Hodgkin’s lymphoma, at a concentration nontoxic to 
normal cells and these effects may be associated with functional inhibition of Hsp90 chaperon.   
These results suggest that dietary FX or fucoxanthinol could be potentially helpful for the treatment of 
PEL [34]. 
5.3. Anti-Obesity Activity 
The increasing incidence of obesity is becoming one of most important medical problems. The 
identification of substances that can decrease or prevent obesity remains a main goal of medical 
research. Adaptive thermogenesis by uncoupling protein-1 (UCP1) could be a physiological defense 
against obesity [35]. UCP1 expression is known to be a significant component of whole body energy 
expenditure, and its dysfunction contributes to the development of obesity [36].  
During normal metabolism the body produces heat. FX increases the amount of energy released as 
heat in fat tissue, a process also called thermogenesis. UCP1 induction by FX metabolites accumulated 
in WAT is of great interest, because, UCP1 is normally expressed only in brown adipose tissue   
(BAT) and not in WAT. This protein, situated in the mitochondrial inner membrane, dissipates the  
pH-gradient generated by oxidative phosphorylation, releasing chemical energy as heat. UCP1 
expression in WAT by FX intake leads to oxidation of fatty acids and heat production in WAT [37].  
UCP families are found in many types of tissue such as BAT (UCP1, UCP2 and UCP3), WAT 
(UCP2), skeletal muscle (UCP2 and UCP3), and brain tissue (UCP4 and UCP5) [38]. UCP1 gene 
expression is increased by cold, adrenergic stimulation, β3-agonists, retinoids and thyroid hormone. 
This adaptive thermogenesis by UCP1 induction in BAT plays an important role in energy balance by 
dissipating excess energy intake as heat to resist body weight gain. UCP1 expression in BAT is known 
as a significant component of whole body energy expenditure, at least in small rodents, and its Mar. Drugs 2012, 10              
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dysfunction contributes to the development of obesity. In contrast to rodents, humans have not great 
amounts of BAT. Considered as a breakthrough discovery for an ideal therapy for obesity, the 
regulation of UCP1 expression in tissues other than BAT by food constituents would also be 
important. FX was found to induce both protein and mRNA expression of UCP1 in WAT [39]. This 
finding will give a clue for new dietary anti-obesity therapies. FX intake promotes mRNA expression 
of β3-adrenergic receptor (Adrb3) in WAT of obese model mice [40]. Adrb3 is mainly expressed in 
BAT and WAT. The up-regulation of Adrb3 expression is considered to be responsible for lipolysis 
and thermogenesis. Thus FX metabolites may promote sensitivity to sympathetic nerve stimulation and 
the up-regulation of fat oxidation in WAT. Another study showed the regulatory effect of FX 
metabolites on peroxisome proliferator-activated receptor γ  (PPARγ) expression in adipose tissue, 
which is an important modulator for UCP1 expression [41]. 
All these promising scientific findings have been obtained through animal studies, and therefore the 
FX, to keep its promises as an anti-obesity nutraceutical, needs to be extensively tested on humans. 
Only one study has been conducted in humans which has evaluated the effectiveness of FX 
supplementation for weight loss. In this work Abidov et al. [42] tested the FX in 151 non-diabetic, obese 
premenopausal women. Three quarters of participants were affected by nonalcoholic fatty liver disease 
(NAFLD), while the remaining had a normal liver function. The women were divided into two groups 
and invited to take respectively 600 mg of Xanthigen, which contains 300 mg pomegranate seed oil 
(PSO) and 300 mg brown seaweed extract containing 2.4 mg FX or a placebo for 16 weeks. The diet 
was reduced to 1800 kcal per day and was composed of 50% carbohydrates, 30% protein and 20% fat. 
The results provided a significant reduction of body weight, fat and systolic/diastolic blood pressure; 
decreased levels of TG and of some enzymes (C-reactive protein (CRP), glutamic pyruvic 
transaminase (GPT), glutamic oxaloacetic transaminase (GOT), γ-glutamyl transpeptidase (γGT), and 
significant increase in resting energy expenditure (REE) measured by indirect calorimetry. The   
16-week supplementation with 4.0 mg/day FX showed an important increase in REE and an even 
greater increase in the group taking FX at a dose of 8 mg [34]. Obese patients with NAFLD commonly 
present elevated markers of liver inflammation and injury, including CRP, GOT, GPT and γGT [43]. A 
significant reduction in body weight and fat in obese individuals results in the down-regulation of 
inflammatory markers and prevent MS. It has been demonstrated that increased GPT and CRP plasma 
levels are associated with decreased hepatic insulin sensitivity, insulin resistance and an increased risk 
for the onset of MS and type 2 diabetes. Judging from this human trial, the FX levels of several brown 
seaweed lipids will be high enough to show their physiological activity when these materials are 
applied to general foods. 
5.4. Antidiabetic Activity 
The potential antidiabetic effects of FX are attributable to the ability of this molecule to induce 
weight loss and WAT reduction. The adipocyte has recently been recognized as an endocrine cell for 
its role in the secretion of biologically active mediators, termed adipokines/chemokines, including 
leptin, adiponectin, resistin, tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 
(MCP-1). Some adipokines are reported to alter insulin sensitivity and glucose and lipid metabolism in 
muscle, liver and adipose tissues [44]. The participation of macrophages in inflammatory responses by Mar. Drugs 2012, 10              
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the release of pro-inflammatory mediators (TNF-α and MCP-1) under obesity conditions has also been 
reported. The chronic low-grade inflammation elicited by pro-inflammatory mediators in the WAT 
leads to insulin resistance [45]. FX and its metabolites prevent the development of diabetes in a model 
of obese/diabetic mice (KK-Ay), but not in lean C57BL/6J mice through down-regulation of MCP-1, 
TNF-α, IL-6 and PAI-1 mRNA expression in the WAT of KK-Ay mice fed FX. The regulatory effect 
of FX on glucose transporter 4 (GLUT4) expression, found in muscle of normal mice fed a high-fat 
diet, is also related to the antidiabetic effect of FX. Skeletal muscle accounts for nearly 40% of body 
mass, and its role in the insulin-induced stimulation of glucose uptake is well documented [46]. The 
administration of a FX-containing diet promoted the recovery of blood glucose uptake to muscle by 
the up-regulation of GLUT4 mRNA expression. Another marked effect of FX on adipocytokine 
secretion was a significant decrease in plasminogen activator inhibitor-1 (PAI-1) mRNA expression in 
WAT of KK-Ay mice [47]. The PAI-1 mRNA level is over-expressed in obese adipose tissue. Increase 
in PAI-1 has been reported to be linked not only to thrombosis and fibrosis but also to obesity and 
insulin resistance. In addition, FX and fucoxanthinol affect peroxisome proliferator-activated receptor 
γ (PPARγ) and promote gene expression related to lipid metabolism in adipocytes [48]. The results of 
a recent work, using cultivated cells, showed that fucoxanthinol prevents inflammation and insulin 
resistance also by inhibiting nitric oxide (NO) and PGE2 production through the down-regulation of 
iNOS and COX-2 mRNA expression as well as adipocytokine production in WAT. iNOS is an enzyme 
that produces NO, which is a free radical molecule related to the pathogenesis of inflammation. The 
over-expression of iNOS mRNA has been observed in WAT of obese mice and adipocytes [49]. 
Treatment of diabetic db/db mice with an iNOS inhibitor reversed hyperglycaemia and improved 
insulin sensitivity, showing that the down-regulation of iNOS mRNA in macrophages is the molecular 
target for the prevention of not only inflammation but also type-2 diabetes. COX-2 is an inducible 
enzyme that produces prostaglandin E2 (PGE2), another inflammatory mediator. Pharmacological 
inhibition of COX-2 reduces IL-6 in WAT, which induces insulin resistance.  
5.5. Activity on Cardiovascular System  
Because MS is a collection of risk factors that substantially increase the chances of damage in the 
cardiovascular system (CVS), which can lead to a heart attack or stroke, FX would be very important 
to prevent CV damage. FX acts on the reduction of major cardiovascular risk factors (obesity, diabetes, 
high blood pressure, chronic inflammation, plasma and hepatic triglyceride, and cholesterol 
concentrations) [50,51]. An interesting metabolic benefit of FX administration in rodents is the 
promotion of the synthesis of docosahexaenoic acid (DHA) in the liver, resulting in improvements in 
lipid profile [52]. Experiments on stroke-prone spontaneously hypertensive rats (SHRSP) show the 
possible protective role of FX in CVD. Thirty-three male SHRSP rats, 5 weeks of age, were divided 
into three groups: (1) kaolin group, which was given a normal diet (kaolin is a   
non-nutrient material); (2) Wakame (Undaria Pinnatifida) group (normal diet containing Wakame 
powder); and (3) cellulose group (normal diet containing cellulose). In this study, Wakame delayed the 
incidence of stroke signs and increased the life span of SHRSP [53]. Clinical research also indicated 
that the metabolic boost from taking FX did not stimulate the central nervous system, meaning it did 
not cause jitters or lost sleep like caffeine, nicotine, or thyroid hormones. So the FX may have a Mar. Drugs 2012, 10              
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potential role in the modulation and prevention of human diseases, particularly in reducing the 
incidence of CVD [54]. 
5.6. Anti-Photoaging Activity 
A recent work showed for the first time the protective effect of FX against UVB-induced skin 
photoaging. In this study, Japanese researchers examined the effect of FX on UVB-induced photoaging 
in the skin of hairless mice by evaluating various parameters of photoaging. The results showed that 
the topical application of FX suppresses UV-induced expression in the skin. The antioxidant activity of 
FX might be involved in this anti-angiogenic effect, because ROS stimulate angiogenesis [55]. The 
sunscreen action of FX does not play a major role in its protective effect against UV-induced 
photoaging, because the UVB absorption (290–320 nm) of FX is relatively weak. This finding might 
be useful in the exploitation of FX in cosmetics. However the details of the molecular mechanism of 
the antiangiogenic effect of FX in UV-exposed skin should be addressed in order to determine the 
mechanism of anti-photoaging [56]. 
6. Conclusions  
The versatile effects of FX make this carotenoid of great potential value in the prevention or 
management of MS, obesity and other chronic diseases. The promising results of animal studies should 
encourage researchers to undertake human clinical trials, since we currently have little information 
about the correct dosage of FX and its use in preventing and treating specific diseases.  
As a carotenoid, FX is a powerful antioxidant that protects cells from FRs damage. A diet rich in 
FX could help to reduce body fat accumulation and to modulate blood glucose and insulin levels, 
through the regulation of cytokine secretions from WAT. FX proved safe with no side effects,   
and even provided other health benefits, including improved cardiovascular health, reduction of 
inflammation (a major cause of heart disease), healthy cholesterol and triglycerides levels, improvements 
in blood pressure levels, and healthy liver function [57]. Moreover it has proved to be an effective 
chelator of heavy metals and toxics [58,59]. These findings indicate the functionality of FX rich brown 
algae as an anti-obesity and anti-diabetic functional food [60]. 
Since chemical synthesis of FX is possible but very expensive, the possibility of obtaining this 
precious carotenoid directly from brown seaweeds should not be underestimated. Many brown 
seaweeds contain a sufficient amount of FX, and are rich in vitamins, minerals, dietary fibers, proteins, 
PUFAs, polysaccharides, other carotenoids, phlorotannins and various functional polyphenols. Thanks 
to their content of iodine, they can be used as activator of thyroid function. Moreover, thanks to their 
content in alginates and mucilage, these algae have the ability to reduce appetite and even the intestinal 
absorption of carbohydrates and fats thereby having a synergistic action with FX [61–63]. 
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